led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
Company profile
Ticker
CMRX
Exchange
Website
CEO
Michael Sherman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Oncoceutics, Inc. ...
IRS number
330903395
CMRX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Chimerix Appoints Marc D. Kozin to Board of Directors
21 Mar 24
S-3
Shelf registration
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
29 Feb 24
8-K
Chimerix Appoints Lisa Decker to Board of Directors
29 Dec 23
8-K
Departure of Directors or Certain Officers
4 Dec 23
8-K
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
16 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
Transcripts
CMRX
Earnings call transcript
2023 Q4
29 Feb 24
CMRX
Earnings call transcript
2023 Q3
2 Nov 23
CMRX
Earnings call transcript
2023 Q2
3 Aug 23
CMRX
Earnings call transcript
2023 Q1
4 May 23
CMRX
Earnings call transcript
2023 Q1
4 May 23
CMRX
Earnings call transcript
2022 Q4
2 Mar 23
CMRX
Earnings call transcript
2022 Q3
5 Nov 22
CMRX
Earnings call transcript
2022 Q2
9 Aug 22
CMRX
Earnings call transcript
2022 Q1
16 May 22
CMRX
Earnings call transcript
2021 Q4
1 Mar 22
Latest ownership filings
4
MARC D KOZIN
21 Mar 24
3
MARC D KOZIN
21 Mar 24
4
Michael T. Andriole
16 Feb 24
4
Michelle LaSpaluto
16 Feb 24
4
David Jakeman
16 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
144
Notice of proposed sale of securities
14 Feb 24
SC 13G/A
Rubric Capital Management LP
12 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.12 mm | 14.12 mm | 14.12 mm | 14.12 mm | 14.12 mm | 14.12 mm |
Cash burn (monthly) | 1.99 mm | 21.68 mm | 8.90 mm | 8.01 mm | 5.98 mm | 6.21 mm |
Cash used (since last report) | 13.74 mm | 149.43 mm | 61.32 mm | 55.18 mm | 41.20 mm | 42.79 mm |
Cash remaining | 376.02 k | -135.31 mm | -47.20 mm | -41.06 mm | -27.08 mm | -28.67 mm |
Runway (months of cash) | 0.2 | -6.2 | -5.3 | -5.1 | -4.5 | -4.6 |
Institutional ownership, Q3 2023
48.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 78 |
Opened positions | 8 |
Closed positions | 26 |
Increased positions | 19 |
Reduced positions | 28 |
13F shares | Current |
---|---|
Total value | 35.72 bn |
Total shares | 43.57 mm |
Total puts | 42.80 k |
Total calls | 4.90 k |
Total put/call ratio | 8.7 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 6.50 mm | $6.24 bn |
Monaco Asset Management SAM | 4.38 mm | $4.20 bn |
Vanguard | 4.35 mm | $4.17 bn |
Cantex Pharmaceuticals | 3.50 mm | $22.51 mm |
Armistice Capital | 2.87 mm | $2.76 bn |
Citadel Advisors | 2.43 mm | $2.33 bn |
Acadian Asset Management | 2.04 mm | $1.96 mm |
MSD Partners | 2.00 mm | $1.92 bn |
Millennium Management | 1.81 mm | $1.74 bn |
GS Goldman Sachs | 1.17 mm | $1.12 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Mar 24 | Marc D Kozin | Stock Option Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 100,000 |
14 Feb 24 | Andriole Michael T. | Common Stock | Sell | Dispose S | No | Yes | 1.0375 | 1,744 | 1.81 k | 447,021 |
14 Feb 24 | Michelle LaSpaluto | Common Stock | Sell | Dispose S | No | Yes | 1.0426 | 1,940 | 2.02 k | 110,999 |
14 Feb 24 | David Jakeman | Common Stock | Sell | Dispose S | No | Yes | 1.0439 | 2,660 | 2.78 k | 141,232 |
News
WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."
11 Apr 24
HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
1 Mar 24
Earnings Scheduled For February 29, 2024
29 Feb 24
Preview: Chimerix's Earnings
28 Feb 24